Clinical cancer research : an official journal of the American Association for Cancer Research
Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609).
Manmeet S Ahluwalia, Sophie Solomon, Sandip P Patel, Zouina Sarfraz, Megan Othus, Young K Chae, Razelle Kurzrock
Published: 202510.1158/1078-0432.CCR-25-2900
Abstract
PURPOSE: To evaluate the efficacy and safety of dual immune checkpoint inhibitors (ICI) in patients with brain metastases (BM) from rare cancers. PATIENTS AND METHODS: Patients with and without BM received nivolumab (240 mg every two weeks) and ipili…
Preview only. Read the full abstract at the source